Literature DB >> 33011248

An innovative wax-based enteric coating for pharmaceutical and nutraceutical oral products.

Rober Habashy1, Mouhamad Khoder2, Sitong Zhang3, Beatriz Pereira1, Marton Bohus1, Julie Tzu-Wen Wang3, Abdullah Isreb1, Mohamed A Alhnan4.   

Abstract

In this work, a novel enteric coating based on natural waxes and alginate was reported. Initially, theophylline tablets were coated with emulsified ceresin wax in heated aqueous alginate solution using a fluidised bed coating technology. A coating level of 10% proved sufficient to prevent tablets from uptaking gastric medium (<5%) and produced a delayed release profile that complies to the pharmacopeial criteria of enteric coating release. Then, a wide range of emulsions based on other natural waxes (white beeswax, yellow beeswax, cetyl palmitate, carnauba wax or rice bran wax) yielded coatings with similar disintegration times and release profiles. Interestingly, the ceresin-based coating showed a superior performance at inhibiting acid uptake and enabling highly pH-responsive drug release in comparison to different commercially available GRAS enteric coating products (Eudraguard® Control, Swanlac® ASL10, and Aquateric™ N100). The coating was stable for 6 months at 30 °C and 65% RH. This innovative approach of applying hot O/W emulsion of natural waxes yielded an aesthetically attractive and stable coating with gastric protection and pH-sensitive release properties. The novel coating can be an efficient and promising alternative to overcome the shortcomings of current GRAS grade enteric coating products.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Delayed release; GRAS; Gastric protection; Nutraceutics; Probiotics; e/c

Mesh:

Substances:

Year:  2020        PMID: 33011248     DOI: 10.1016/j.ijpharm.2020.119935

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  1 in total

1.  A Novel Multilayer Natural Coating for Fed-State Gastric Protection.

Authors:  Rober Habashy; Mouhamad Khoder; Abdullah Isreb; Mohamed A Alhnan
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.